HRP20090516T1 - Formulation of a thienopyridine platelet aggregation inhibitor - Google Patents

Formulation of a thienopyridine platelet aggregation inhibitor

Info

Publication number
HRP20090516T1
HRP20090516T1 HR20090516T HRP20090516T HRP20090516T1 HR P20090516 T1 HRP20090516 T1 HR P20090516T1 HR 20090516 T HR20090516 T HR 20090516T HR P20090516 T HRP20090516 T HR P20090516T HR P20090516 T1 HRP20090516 T1 HR P20090516T1
Authority
HR
Croatia
Prior art keywords
formulation
platelet aggregation
aggregation inhibitor
thienopyridine
thienopyridine platelet
Prior art date
Application number
HR20090516T
Other languages
English (en)
Croatian (hr)
Inventor
Brian Dziennik David
Beth Edelman Tamara
Lloyd Oren Peter
Louis Ternik Robert
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20090516T1 publication Critical patent/HRP20090516T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HR20090516T 2005-06-10 2009-09-25 Formulation of a thienopyridine platelet aggregation inhibitor HRP20090516T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10
PCT/US2006/021860 WO2006135605A2 (en) 2005-06-10 2006-06-06 Formulation of a thienopyridine platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
HRP20090516T1 true HRP20090516T1 (en) 2009-10-31

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090516T HRP20090516T1 (en) 2005-06-10 2009-09-25 Formulation of a thienopyridine platelet aggregation inhibitor

Country Status (35)

Country Link
US (1) US20080176893A1 (es)
EP (1) EP1896019B1 (es)
JP (1) JP2008543755A (es)
KR (2) KR20080008413A (es)
CN (1) CN101193633B (es)
AR (1) AR054283A1 (es)
AT (1) ATE441413T1 (es)
AU (1) AU2006258102B2 (es)
BR (1) BRPI0611350B8 (es)
CA (1) CA2611668C (es)
CY (1) CY1109502T1 (es)
DE (1) DE602006008942D1 (es)
DK (1) DK1896019T3 (es)
DO (1) DOP2006000126A (es)
EA (1) EA011693B1 (es)
EC (1) ECSP077984A (es)
ES (1) ES2330373T3 (es)
HK (1) HK1116422A1 (es)
HR (1) HRP20090516T1 (es)
IL (1) IL187830A0 (es)
MA (1) MA29688B1 (es)
MX (1) MX2007015431A (es)
MY (1) MY151038A (es)
NO (1) NO20076317L (es)
NZ (1) NZ564003A (es)
PE (1) PE20070320A1 (es)
PL (1) PL1896019T3 (es)
PT (1) PT1896019E (es)
RS (1) RS51194B (es)
SI (1) SI1896019T1 (es)
TN (1) TNSN07466A1 (es)
TW (1) TWI318571B (es)
UA (1) UA91051C2 (es)
WO (1) WO2006135605A2 (es)
ZA (1) ZA200710697B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
WO2008072535A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
TWI405591B (zh) * 2006-12-07 2013-08-21 Daiichi Sankyo Co Ltd 固形製劑之製造方法
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
MX2009009413A (es) * 2007-03-02 2009-09-11 Daiichi Sankyo Co Ltd Metodo para la produccion de clorhidrato de prasugrel de alta pureza.
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
EP2257556A1 (en) * 2008-02-06 2010-12-08 Helm AG Prasugrel salts with improved properties
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
DE602008002820D1 (de) 2008-04-25 2010-11-11 Sandoz Ag Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung
WO2010094471A1 (en) * 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
PT3100728T (pt) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
EP2722037A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Prasugrel formulations
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
PT1728794E (pt) * 2000-07-06 2008-07-15 Ube Industries Sal de adição maleato de derivados de hidropiridina
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
EP1653930B1 (en) * 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin

Also Published As

Publication number Publication date
BRPI0611350B1 (pt) 2020-09-15
ATE441413T1 (de) 2009-09-15
TW200718420A (en) 2007-05-16
EA011693B1 (ru) 2009-04-28
WO2006135605A2 (en) 2006-12-21
MY151038A (en) 2014-03-31
HK1116422A1 (en) 2008-12-24
CN101193633B (zh) 2011-12-14
KR20080008413A (ko) 2008-01-23
ES2330373T3 (es) 2009-12-09
US20080176893A1 (en) 2008-07-24
CA2611668C (en) 2013-10-15
CY1109502T1 (el) 2014-08-13
AR054283A1 (es) 2007-06-13
DE602006008942D1 (en) 2009-10-15
EA200702670A1 (ru) 2008-04-28
KR20100076050A (ko) 2010-07-05
JP2008543755A (ja) 2008-12-04
MA29688B1 (fr) 2008-08-01
PE20070320A1 (es) 2007-05-12
MX2007015431A (es) 2008-02-21
ZA200710697B (en) 2009-08-26
TNSN07466A1 (en) 2009-03-17
AU2006258102A1 (en) 2006-12-21
CN101193633A (zh) 2008-06-04
EP1896019A2 (en) 2008-03-12
TWI318571B (en) 2009-12-21
EP1896019B1 (en) 2009-09-02
PT1896019E (pt) 2009-11-19
RS51194B (sr) 2010-10-31
WO2006135605A3 (en) 2007-04-12
BRPI0611350B8 (pt) 2021-05-25
UA91051C2 (ru) 2010-06-25
ECSP077984A (es) 2008-01-23
NO20076317L (no) 2008-02-29
PL1896019T3 (pl) 2010-01-29
CA2611668A1 (en) 2006-12-21
IL187830A0 (en) 2008-04-13
DK1896019T3 (da) 2009-10-26
SI1896019T1 (sl) 2010-01-29
DOP2006000126A (es) 2006-12-15
NZ564003A (en) 2011-07-29
AU2006258102B2 (en) 2011-09-15
BRPI0611350A2 (pt) 2010-12-07

Similar Documents

Publication Publication Date Title
HRP20090516T1 (en) Formulation of a thienopyridine platelet aggregation inhibitor
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
EP3586631A3 (en) Plant health composition
DK1848659T3 (da) Oxygenopfangningssammensætninger og emballage omfattende sammensætningerne
TR201908611T4 (tr) Hububatta mantarla mücadeleye yönelik epoksikonazol içeren sinerjistik fungisidal karışımlar.
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
EA200801859A1 (ru) Неводная композиция стабильного витамина "c", способ ее приготовления и применения
ECSP088294A (es) Formulación en aerosol para la inhalación de beta-agonistas
WO2008049042A3 (en) Ophthalmic compositions containing diglycine
CY1122084T1 (el) Συνθεσεις που περιλαμβανουν αμλοδιπινη και μπισοπρολολη
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
NO20085317L (no) Imidazoazepinonforbindelser
MX337380B (es) Composiciones pesticidas.
AR046254A1 (es) Productos farmaceuticos estables
FR2893924B1 (fr) Paquet d'articles comprenant un flanc le recouvrant partiellement et un film enveloppant le tout.
SV2006002238A (es) Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh
CR10690A (es) Nuevos derivados de fluoreno, composiciones que los contienen y utilizacion como inhibidores de la proteina chaperona hsp90
MA31678B1 (fr) Composition therapeutique aromatisee a base d'argile
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
EA200700689A1 (ru) Сохраняющая свежесть упаковка для удлиненных изделий
SG163490A1 (en) Packaging body
ATE324869T1 (de) Blisterverpackung und feste dosierungsform enthaltend desmopressin
PA8593701A1 (es) [4-(3-aminometilfenil)piperidin-1-il]-[5-(2-fluorofenil-etinil)furan-2-il]-metanoma como inhibidor de triptasa de mastocitos
TH87282B (th) สูตรผสมของสารยับยั้งการรวมกลุ่มของเกล็ดเลือดชนิดไทอีโนไพริดีน
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent